MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2020-06-09
Last Posted Date
2025-06-29
Lead Sponsor
Pfizer
Target Recruit Count
280
Registration Number
NCT04424303
Locations
🇫🇷

Clinique de l Europe, Amiens, France

🇫🇷

Hopital Sud, Amiens, France

🇫🇷

Hopital Jean Minjoz, Besancon, France

and more 35 locations

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2020-06-04
Last Posted Date
2023-04-07
Lead Sponsor
Pfizer
Target Recruit Count
460
Registration Number
NCT04413617
Locations
🇧🇬

,,UMHAT - Georgi Stranski" EAD, Pleven, Bulgaria

🇧🇬

Medical Diagnostic Laboratory Rusev EOOD, Plovdiv, Bulgaria

🇧🇬

MHAT Plovdiv AD, Plovdiv, Bulgaria

and more 140 locations

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

Phase 2
Withdrawn
Conditions
COVID-19
Interventions
Other: Placebo
First Posted Date
2020-06-02
Last Posted Date
2020-07-31
Lead Sponsor
Pfizer
Registration Number
NCT04412252
Locations
🇺🇸

Hartford Hospital (HH), Hartford, Connecticut, United States

🇺🇸

University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City, Iowa, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

and more 3 locations

Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46

Phase 1
Completed
Conditions
Healthy
Interventions
Biological: TA-46
Other: Placebo
First Posted Date
2020-06-01
Last Posted Date
2020-06-01
Lead Sponsor
Pfizer
Target Recruit Count
78
Registration Number
NCT04410809
Locations
🇳🇱

PRA, Groningen, Netherlands

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Phase 2
Completed
Conditions
Acute Migraine
Interventions
First Posted Date
2020-05-29
Last Posted Date
2023-05-18
Lead Sponsor
Pfizer
Target Recruit Count
974
Registration Number
NCT04408794
Locations
🇺🇸

Medical Affiliated Research Center, Huntsville, Alabama, United States

🇺🇸

Coastal Clinical Research, LLC, An AMR Co., Mobile, Alabama, United States

🇺🇸

Tucson Neuroscience Research, Tucson, Arizona, United States

and more 58 locations

PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-05-27
Last Posted Date
2020-05-27
Lead Sponsor
Pfizer
Target Recruit Count
26
Registration Number
NCT04403776
Locations
🇨🇳

Shuguang Hospital Affiliated to Shanghai University of TCM/Phase I Unit, Shanghai, China

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Phase 2
Completed
Conditions
Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease
Interventions
First Posted Date
2020-05-22
Last Posted Date
2023-04-13
Lead Sponsor
Pfizer
Target Recruit Count
75
Registration Number
NCT04399538
Locations
🇺🇸

Clinical Trials Research, Lincoln, California, United States

🇺🇸

Catalina Research Institute, LLC, Montclair, California, United States

🇺🇸

Excel Medical Clinical Trials, Boca Raton, Florida, United States

and more 16 locations

Actigraphy Improvement With Voxelotor (ActIVe) Study

Phase 4
Completed
Conditions
Sickle Cell Disease
Sickle Cell Anemia
Interventions
First Posted Date
2020-05-22
Last Posted Date
2023-11-21
Lead Sponsor
Pfizer
Target Recruit Count
25
Registration Number
NCT04400487
Locations
🇺🇸

UConn Health, Farmington, Connecticut, United States

🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Children's Hospital of Michigan, Detroit, Michigan, United States

and more 7 locations

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Completed
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2020-05-21
Last Posted Date
2021-11-01
Lead Sponsor
Pfizer
Target Recruit Count
486
Registration Number
NCT04398732
Locations
🇮🇶

Pfizer, Baghdad, Iraq

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Phase 4
Completed
Conditions
Hemophilia A
Interventions
Biological: Moroctocog-alfa (AF-CC)
First Posted Date
2020-05-20
Last Posted Date
2021-05-03
Lead Sponsor
Pfizer
Target Recruit Count
50
Registration Number
NCT04396639
Locations
🇮🇳

Nirmal Hospital, Surat, Gujarat, India

🇮🇳

K.J.Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India

🇮🇳

Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath